Breyanzi is developed by Bristol-Myers Squibb.

What development phase is Breyanzi in?

Breyanzi is FDA-approved (marketed).

What is the generic name of Breyanzi?

LISOCABTAGENE MARALEUCEL is the generic (nonproprietary) name of Breyanzi.

Last reviewed 2026-04-20 · How we verify

Breyanzi (LISOCABTAGENE MARALEUCEL)

Bristol-Myers Squibb · FDA-approved active Gene therapy

At a glance

Generic name	LISOCABTAGENE MARALEUCEL
Sponsor	Bristol-Myers Squibb
Modality	Gene therapy
Therapeutic area	Oncology
Phase	FDA-approved
Annual revenue	1358

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
SEC EDGAR	Revenue + earnings

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Breyanzi CI brief — competitive landscape report
Breyanzi updates RSS · CI watch RSS
Bristol-Myers Squibb portfolio CI